'The T-cell engager teclistamab acts on T cells through CD3 (the defining marker of T cells) and targets plasmablasts and plasma cells through BCMA. Teclistamab has been shown to be highly effective in patients with multiple myeloma.4 Thus, we hypothesized that teclistamab may be effective for targeting severe autoimmune diseases, even after failure of conventional B-cell depletion.'
#Immunology #Immunotherapy #Autoimmunity
https://www.nejm.org/doi/full/10.1056/NEJMc2408786